Re-treatment versus extended treatment strategy of systemic bevacizumab in hereditary hemorrhagic telangiectasia: which is better?

Ann Hematol. 2018 Sep;97(9):1727-1729. doi: 10.1007/s00277-018-3324-7. Epub 2018 Apr 14.

Narendranath Epperla^{1

2}, Ariel Kleman³, Matthew Karafin^{4

5}, Patrick Foy⁶

¹ Division of Hematology, The Ohio State University, 320W 10th Ave, Columbus, OH, 43210, USA. Narendranath.Epperla@osumc.edu.
² Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA. Narendranath.Epperla@osumc.edu.
³ Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
⁴ Department of Pathology, Medical College of Wisconsin, Milwaukee, WI, USA.
⁵ Medical Sciences Institute, BloodCenter of Wisconsin, Milwaukee, WI, USA.
⁶ Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.

No abstract available

Publication types